MDM2 and osteosarcoma: MDM2-ALT1 splicing variant was found to be upregulated upon ultra-violet (UV) or cis-platinum treatment in osteosarcoma as well as breast and lung carcinomas bearing wild-type or deleted TP53, respectively, suggesting that MDM2-ALT1 production may be independent of TP53 status [26].